BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-969 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-969\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06318273-11138@assetmemo.bio
DTSTAMP:20261121T005736Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:ABBV-969: Phase 1 readout est. (NCT06318273)
DESCRIPTION:ABBV-969\, phase 1\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: A Study to Assess Adverse Events\, and How Intravenously (I
 V) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Me
 tastatic Castration-Resistant Prostate Cancer\nEstimated primary completio
 n: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abbv-969
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063
 18273
URL:https://assetmemo.bio/drug/abbv-969#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
